Pharmacokinetic parameters

Related by string. pharmacokinetic parameters * Pharmacokinetics . pharmacokinetics . pharmacokinetic : pharmacokinetics PK . pharmacokinetic PK . safety tolerability pharmacokinetics . favorable pharmacokinetic profile . safety tolerability pharmacokinetic / Parameters . PARAMETERS : physiological parameters . metabolic parameters . qualitative parameters . pharmacodynamic parameters * *

Related by context. Frequent words. (Click for all words.) 69 fasting plasma glucose FPG 67 Pharmacokinetic 66 CIMZIA TM 66 teriflunomide 65 univariate 65 Response Evaluation Criteria 65 pharmacodynamic effects 65 NPH insulin 65 plus prednisone 65 APTIVUS r 65 μg kg 64 GSK# [001] 64 tolerability profiles 64 PREZISTA r 64 pharmacokinetic parameters 64 tapentadol ER 64 lopinavir r arm 64 administered subcutaneously 64 irbesartan 64 ARCOXIA 64 Angiographic 63 ACR# response 63 QTc prolongation 63 posttreatment 63 mg kg dose 63 Secondary endpoints include 63 sustained virological response 63 lispro 63 darbepoetin alfa 63 plus dexamethasone 63 APTIVUS 63 Baseline characteristics 63 RECIST criteria 63 peginterferon alfa 63 Pegasys ® 63 oxcarbazepine 63 fluvastatin 63 docetaxel chemotherapy 63 lanthanum carbonate 63 lopinavir r 63 #mg/m# [002] 63 lipid lowering agents 62 achieved statistical significance 62 Montgomery Asberg Depression 62 MERLIN TIMI 62 seroprotection 62 Am J Cardiol 62 mg BID 62 ARIKACE 62 analgesic efficacy 62 efficacy endpoint 62 transaminases 62 elotuzumab 62 DOXIL 62 daunorubicin 62 metabolic parameters 62 peripheral blood mononuclear 62 peg IFN 62 interferon alfa 62 CCX# 62 Engerix B 62 hemoglobin A1c HbA1c 62 undetectable HCV RNA 62 apolipoprotein B 62 exhaled nitric oxide 62 xenograft models 62 #mg/day [001] 62 events SAEs 62 pharmacokinetics PK 62 liposomal formulation 62 chlorambucil 62 pegylated interferon alpha 62 Solid Tumors 62 limiting toxicity 62 pharmacokinetic PK 62 COPEGUS 62 eszopiclone 62 sensitivity specificity 62 prospectively defined 62 active comparator 62 OGTT 61 LATUDA 61 LIALDA 61 pharmacokinetic profiles 61 mg QD 61 hematologic toxicity 61 Candesartan 61 Secondary endpoints 61 Severity Index PASI 61 Cotinine 61 TAXUS Stent 61 insulin detemir 61 GLYX 61 Psoriasis Area 61 peginterferon alfa 2b 61 Natural Catastrophe Stress 61 virologic response 61 sipuleucel T 61 bendamustine 61 hypophosphatemia 61 immunostaining

Back to home page